Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
Reich
Kristian
K
Dermatologikum Hamburg, Hamburg, Germany.
Schenkel
Brad
B
Zhao
Ning
N
Szapary
Philippe
P
Augustin
Matthias
M
Bourcier
Marc
M
Guenther
Lyn
L
Langley
Richard G
RG
D000041:Absenteeism; D000328:Adult; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010147:Pain Measurement; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D011788:Quality of Life; D012720:Severity of Illness Index; D013647:Task Performance and Analysis; D016896:Treatment Outcome; D000069549:Ustekinumab; D014937:Work
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069549:Ustekinumab